GlassScriptPhysician profile
Michael W Toulan
NPI 1316920994
$4,058.13
in general payments reported to CMS, 2019-2025
37 companies · $639 in 2025
The $639 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $368 · 2021: $472 · 2022: $617 · 2023: $780 · 2024: $453 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $828.17 | 2019-2024 | Myrbetriq |
| Boston Scientific Corporation | $572.58 | 2019-2025 | Moses 550 D\F\L, Lithovue, Greenlight Xps |
| Janssen Biotech, INC. | $352.08 | 2019-2023 | Erleada |
| Procept Biorobotics Corporation | $255.97 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Abbvie INC. | $230.33 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $162.57 | 2019-2025 | Adstiladrin |
| Convatec INC. | $135.88 | 2022-2024 | |
| Coloplast Corp | $126.80 | 2020-2025 | Saffron, Titan |
| Dendreon Pharmaceuticals LLC | $104.48 | 2020-2025 | Provenge |
| Urogen Pharma, INC. | $102.56 | 2024-2025 | |
| Teleflex LLC | $97.17 | 2021-2025 | Barrigel, Urolift |
| Myovant Sciences INC. | $89.89 | 2021 | |
| Avation Medical, INC. | $86.76 | 2025 | Vivally System |
| Sumitomo Pharma America, INC. | $81.85 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $75.43 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $69.57 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $65.03 | 2024-2025 | |
| 180 Medical, INC. | $57.05 | 2023-2024 | Gentlecath |
| Innovation Technologies INC | $56.83 | 2023-2024 | Irrisept |
| Pfizer INC. | $55.13 | 2019-2021 | |
| Cook Medical LLC | $53.87 | 2020-2024 | Resonance |
| Neotract INC. | $38.71 | 2020 | |
| Merck Sharp & Dohme LLC | $37.72 | 2021-2023 | Lynparza, Keytruda, Welireg |
| Baxter Healthcare | $34.74 | 2025 | Floseal |
| Genzyme Corporation | $34.51 | 2019 | |
| Cycle Pharmaceuticals INC | $27.40 | 2024 | Tiopronin |
| Axonics, INC. | $25.47 | 2022 | |
| Endo USA, INC. | $23.91 | 2025 | Aveed, Xiaflex |
| Ambu INC. | $23.44 | 2020 | |
| Medtronic, INC. | $22.41 | 2022 | |
| Isoray, INC | $22.28 | 2020 | |
| Valencia Technologies Corporation | $19.31 | 2025 | Ecoin Device Kit |
| Abc Home Medical Supply, INC. | $19.08 | 2025 | |
| Olympus America INC. | $18.47 | 2023 | Olympus |
| Tolmar, INC. | $17.66 | 2024 | |
| Laborie Medical Technologies Corp. | $16.84 | 2023 | |
| Tela Bio, INC. | $16.18 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Toulan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.